Solid lipid nanoparticles: a promising technology for delivery of poorly water-soluble drugs
ACTA Pharmaceutica Sciencia · 2018
DOI: 10.23893/1307-2080.aps.05616 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACTA Pharmaceutica Sciencia, 2018. Verfasst von Shailendra Bhatt und 3 weiteren Autor:innen. Die Arbeit wurde bisher 16-mal zitiert (Crossref).
Abstract (Originalsprache)
Oral administration of drugs having low water solubility is hampered by various enzymatic barriers present in gastrointestinal (GI) tract.Lipid nanoparticles based on solid matrix have emerged as a potential drug delivery system to improve the absorption and bioavailability of several drugs, especially lipophilic compounds.Solid lipid nanoparticles (SLN) are reported as the most promising technology for oral administration and offered several advantages over conventional dosages formulations including, enhancement in solubility, stability, permeability, and bioavailability with minimal side effects.In this review, we have highlighted recent advances in the development of SLN for the oral, parenteral, rectal, and topical administration of various drugs.We have also summarized the applications of SLN in the treatment of various diseases like tuberculosis, cancer, diabetes, and several nervous system related disorders.
Zitieren
APA
Bhatt, S., Sharma, J., Singh, M., & Saini, V. (2018). Solid lipid nanoparticles: a promising technology for delivery of poorly water-soluble drugs. ACTA Pharmaceutica Sciencia. https://doi.org/10.23893/1307-2080.aps.05616
Vancouver
Bhatt S, Sharma J, Singh M, Saini V. Solid lipid nanoparticles: a promising technology for delivery of poorly water-soluble drugs. ACTA Pharmaceutica Sciencia. 2018. doi:10.23893/1307-2080.aps.05616
BibTeX
@article{Bhatt2018,
author = {Bhatt, Shailendra and Sharma, Jaibharti and Singh, Manishkumar and Saini, Vipin},
title = {Solid lipid nanoparticles: a promising technology for delivery of poorly water-soluble drugs},
journal = {ACTA Pharmaceutica Sciencia},
year = {2018},
doi = {10.23893/1307-2080.aps.05616}
}
EUVIMED